-=Edwards Lifesciences (EW) reported earnings on Thur 1 Feb 2018 (a/h)

Edwards Lifesciences beats by $0.03, beats on revs; guides Q1 EPS above consensus, revs above consensus; guides FY18 EPS above consensus, revs in-line

• Reports Q4 (Dec) earnings of $0.94 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.91; revenues rose 15.7% year/year to $888.5 mln vs the $868.45 mln Capital IQ Consensus.
• "Our strong 2017 reinforces our confidence in our focused innovation strategy and longer term outlook, and we look forward to an exciting 2018 as we continue to aggressively invest in our future. We expect to achieve a number of important milestones supporting progress in the development of transformative therapies across all of our product lines. Our differentiated strategy continues to benefit patients and serve us well as we plan for future growth and value creation."
• Co issues upside guidance for Q1, sees EPS of $1.04-1.14, excluding non-recurring items, vs. $1.04 Capital IQ Consensus Estimate; sees Q1 revs of $900-950 mln vs. $904.98 mln Capital IQ Consensus Estimate.
• Co issues guidance for FY18, sees EPS of $4.43-4.63, excluding non-recurring items, vs. $4.27 Capital IQ Consensus Estimate; sees FY18 revs of $3.5-3.9 bln vs. $3.74 bln Capital IQ Consensus Estimate. 

=Edwards Lifesciences (EW) reported earnings on Wed 25 Oct 2017 (b/o)

Edwards Lifesciences misses by $0.02, misses on revs; guides Q4 EPS in-line, revs in-line

• Reports Q3 (Sep) earnings of $0.84 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of $0.86; revenues rose 11.1% year/year to $821.5 mln vs the $833.85 mln Capital IQ Consensus.
• Co issues in-line guidancefor Q4, sees EPS of $0.84-0.94, excluding non-recurring items, vs. $0.91 Capital IQ Consensus Estimate; sees Q4 revs of $855-895 mln vs. $869.55 mln Capital IQ Consensus Estimate.

=Edwards Lifesciences (EW) reported earnings on Tue 25 Apr 2017 (a/h)

Edwards Lifesciences beats by $0.12, beats on revs; guides Q2 EPS in-line, revs in-line; raises FY17 EPS guidance, narrows revs outlook :

• Reports Q1 (Mar) earnings of $0.94 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus of $0.82; revenues rose 26.7% year/year to $883.5 mln vs the $776.51 mln Capital IQ Consensus.
• On an underlying basis sales grew 19.1 percent over the first quarter last year. Underlying sales growth excludes the impact of the Germany stocking sales, as customers in Germany elected to purchase additional inventory of the SAPIEN 3 valve in anticipation of a potential supply interruption resulting from recent intellectual property litigation.
• For the quarter, the company's gross profit margin was 75.6 percent, compared to 74.1 percent in the same period last year. This increase was driven primarily by a more profitable product mix, led by growing sales of transcatheter valves, partially offset by the impact from foreign exchange.
• Co issues in-line guidance for Q2, sees EPS of $0.82-0.92, excluding non-recurring items, vs. $0.87 Capital IQ Consensus Estimate; sees Q2 revs of $810-850 mln vs. $825.83 mln Capital IQ Consensus Estimate.
• Co updates guidance for FY17, sees EPS of $3.43-3.55 (Prior $3.30-3.45) vs. $3.41 Capital IQ Consensus Estimate; sees FY17 revs of $3.2-3.4 bln (Prior $3.0-3.4 bln) vs. $3.26 bln Capital IQ Consensus Estimate.

=Edwards Lifesciences (EW) reported earnings on Tue 25 Oct 2016 (a/h)

Edwards Lifesciences reports EPS in-line, misses on revs; guides Q4 EPS in-line, revs below consensus  :

• Reports Q3 (Sep) earnings of $0.68 per share, in-line with the Capital IQ Consensus of $0.68; revenues rose 20.1% year/year to $739.4 mln vs the $749.07 mln Capital IQ Consensus.
• For the quarter, the company's gross profit margin was 72.8 percent, compared to 76.2 percent in the same period last year. This decrease, which was expected, was driven predominately by foreign exchange.
• Co issues guidance for Q4, sees EPS of $0.67-0.77 vs. $0.74 Capital IQ Consensus Estimate; sees Q4 revs of $750-790 mln vs. $801.51 mln Capital IQ Consensus Estimate.
• "As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing in our future, consistent with our focused innovation strategy. We are confident these investments will result in innovative therapies that will enable us to treat a broader group of patients and drive continued strong organic growth."